Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for R/R Acute Myeloid Leukemia

Jacob Herstein, Fadi Haddad, Kelly Chien, Yesid Alvarado Valero, Danielle Hammond, Naval Daver, Tapan Kadia, Farhad Ravandi, Kayleigh Marx, Courtney DiNardo

Blood (2025) 146 (Supplement 1): 6981.

https://doi.org/10.1182/blood-2025-6981

Published: 2025

Journal Articles

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor

Fadi Haddad, Hagop Kantarjian, Sara Dellasala, Ghayas Issa, Tapan Kadia, Jayastu Senapati, Rita Khouri, Nicholas Short, Courtney DiNardo, Nitin Jain, Hussein Abbas, Kelly Chien, Anwesha Ray, Naveen Pemmaraju, Farhad Ravandi, Guillermo Garcia-Manero, Koji Sasaki, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5564.

https://doi.org/10.1182/blood-2025-5564

Published: 2025

Journal Articles

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

Sankalp Arora, Koji Sasaki, Nicholas Short, Nitin Jain, Farhad Ravandi, Fadi Haddad, Jayastu Senapati, Guillermo Montalban-Bravo, Alexandre Bazinet, Rita Khouri, Rebecca Garris, Hagop Kantarjian, Elias Jabbour

Blood (2025) 146 (Supplement 1): 759.

https://doi.org/10.1182/blood-2025-759

Published: 2025

Journal Articles

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Hannah Goulart, Elias Jabbour, Nitin Jain, Farhad Ravandi, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alex Bataller, Fadi Haddad, Rita Khouri, Jayastu Senapati, Rebecca Garris, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2025-3350

Published: 2025

Journal Articles

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission

Hannah Goulart, Elias Jabbour, Nitin Jain, Fadi Haddad, Jayastu Senapati, Rita Khouri, Guillermo Garcia-Manero, William Wierda, Farhad Ravandi, Naveen Pemmaraju, Kelly Chien, Rebecca Garris, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2025-3348

Published: 2025

Journal Articles

Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia

Hannah Goulart, Hagop Kantarjian, Nitin Jain, Jayastu Senapati, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Koji Sasaki, Fadi Haddad, Guillermo Garcia-Manero, Rebecca Garris, Nicholas Short

Blood (2025) 146 (Supplement 1): 5131.

https://doi.org/10.1182/blood-2025-5131

Published: 2025

Journal Articles

Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial

Issa Khouri, Susan Wu, Fadi Haddad, Denai Milton, Tapan Kadia, Nicholas Short, Koji Sasaki, Jin Im, David Marin, Rohtesh Mehta, Gabriela Rondon, Hind Rafei, Jeremy Ramdial, Guillermo Garcia-Manero, Dan Li, Alison Gulbis, Bouthaina Dabaja, Elias Jabbour, Qing Ma

Blood (2025) 146 (Supplement 1): 6022.

https://doi.org/10.1182/blood-2025-6022

Published: 2025

Journal Articles

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial

Fadi Haddad, Elias Jabbour, Ghayas Issa, Koji Sasaki, Rita Khouri, Alex Bataller, Jayastu Senapati, Tapan Kadia, Guillermo Montalban-Bravo, Naveen Pemmaraju, Anwesha Ray, Sara Dellasala, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2025-5565

Published: 2025

Journal Articles

Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase

Mina Abdelmalek, Farah Al Haj, Fadi Haddad, William Wierda, William D. Marrero, Naveen Pemmaraju, Danielle Hammond, Yesid Alvarado Valero, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Tapan Kadia

Blood (2025) 146 (Supplement 1): 2010.

https://doi.org/10.1182/blood-2025-2010

Published: 2025

Journal Articles

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

Fadi Haddad, Hagop Kantarjian, Mauricette Michallet, Christophe Bouvier, Ghayas Issa, Koji Sasaki, Julien Bollard, Julie Hildt, Sara Dellasala, Vincent Alcazer, Elias Jabbour, Franck Nicolini

Blood (2025) 146 (Supplement 1): 5550.

https://doi.org/10.1182/blood-2025-5550

Published: 2025

Journal Articles

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Sara Nofal, Jennifer Marvin-Peek, Sanam Loghavi, Jayastu Senapati, Bofei Wang, Fadi Haddad, Nicholas Short, Naval Daver, Ghayas Issa, Koji Sasaki, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Ehsan Irajizad, Hussein Abbas

Blood (2025) 146 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2025-3503

Published: 2025

Journal Articles

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Jayastu Senapati, Elias Jabbour, Nitin Jain, Kelly Chien, Musa Yilmaz, Fadi Haddad, Guillermo Montalban-Bravo, Eitan Kugler, Wei-Ying Jen, Rita Khouri, Maro Ohanian, Rebecca Garris, Min Zhao, Guillermo Garcia-Manero, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1573.

https://doi.org/10.1182/blood-2025-1573

Published: 2025

Journal Articles

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

Hannah Goulart, Elias Jabbour, Nitin Jain, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Kelly Chien, Fadi Haddad, Jayastu Senapati, Rita Khouri, Farhad Ravandi, Guillermo Garcia-Manero, Rebecca Garris, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2025-1571

Published: 2025

Journal Articles

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Hannah Goulart, Hagop Kantarjian, Nitin Jain, Rita Khouri, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alessandra Ferrajoli, Alex Bataller, Fadi Haddad, Jayastu Senapati, Guillermo Garcia-Manero, Rebecca Garris, Farhad Ravandi, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2025-1567

Published: 2025

Journal Articles

Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring

Trevor Jamison, Elias Jabbour, Nitin Jain, Omer Karrar, Fadi Haddad, Partow Kebriaei, Issa Khouri, Uday Popat, Hui Yang, Jayastu Senapati, Eitan Kugler, Rebecca Garris, Guillermo Garcia-Manero, Hagop Kantarjian, Nicholas Short

Blood (2025) 146 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2025-1558

Published: 2025

Journal Articles

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2025-1556

Published: 2025

Journal Articles

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Grace Park, Hagop Kantarjian, Nicholas Short, Nitin Jain, Farhad Ravandi, Kelly Chien, Jayastu Senapati, Fadi Haddad, Rita Khouri, Tapan Kadia, Naval Daver, Courtney DiNardo, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Naveen Pemmaraju, Rebecca Garris, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2025-1544

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

Jayastu Senapati, Hagop Kantarjian, Tapan Kadia, Naveen Pemmaraju, Courtney DiNardo, Naval Daver, Andres Quesada, Austin Wilson, Kayla Farish, Fadi Haddad, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2025-1724

Published: 2025

Journal Articles

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Vanthana Bharathi, Alexandre Bazinet, Alex Bataller, Naval Daver, Courtney DiNardo, Hussein Abbas, Ian Bouligny, Gautam Borthakur, Fadi Haddad, Naveen Pemmaraju, Steven Kornblau, Wei-Ying Jen, Nicholas Short, Andres Quesada, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3405.

https://doi.org/10.1182/blood-2025-3405

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for R/R Acute Myeloid Leukemia

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission

Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia

Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial

Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only